Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region: Opinion statement from China, Japan, Taiwan, Korea, and Australia

Dingwei Ye*, Masatoshi Eto, Jin Soo Chung, Go Kimura, Wen Cheng Chang, Yen Hwa Chang, See Tong Pang, Jae Lyun Lee, Yuanjie Niu, Howard Gurney, Hirotsugu Uemura

*此作品的通信作者

研究成果: 期刊稿件文獻綜述同行評審

17 引文 斯高帕斯(Scopus)

摘要

Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

原文英語
頁(從 - 到)225-233
頁數9
期刊Clinical Genitourinary Cancer
12
發行號4
DOIs
出版狀態已出版 - 08 2014
對外發佈

指紋

深入研究「Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region: Opinion statement from China, Japan, Taiwan, Korea, and Australia」主題。共同形成了獨特的指紋。

引用此